The apolipoprotein E polymorphism is not associated with response to electroconvulsive therapy in major depressive disorder

The apolipoprotein E (APOE) polymorphism is associated with neurodegenerative diseases. Its role regarding psychiatric disorders is controversial. It has been suggested to affect antidepressant treatment response and response to electroconvulsive therapy (ECT). In the present study, the association between APOE polymorphism and response to ECT in 119 patients with major depressive disorder was investigated. Moreover, a relation between APOE polymorphism and the age of onset of depression as well as the cognitive outcome of ECT was studied. In the whole population, no association was found between APOE polymorphism and response to ECT. However, in nonpsychotic patients, the E;2 allele tended to be more frequent in responders than nonresponders. Earlier onset of depression was observed in the patients with epsilon 4 allele in late-life depression. There was no association between the APOE genotype and the cognitive change caused by ECT in the population as a whole. In women, however, epsilon 2 allele may play a protective and epsilon 4 allele a deleterious role in cognition during ECT.